Navigation Links
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/18/2007

at PTC124 is potentially applicable to a broad range of other genetic disorders in which a nonsense mutation is the cause of the disease. The FDA has granted PTC124 Fast-Track designations and Orphan Drug designations for the treatment of CF and DMD due to nonsense mutations. PTC124 has also been granted orphan drug status for the treatment of CF and DMD by the European Commission. PTC124's development is supported by grants from the Muscular Dystrophy Association (MDA), Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), Parent Project Muscular Dystrophy (PPMD), FDA's Office of Orphan Products Development (OOPD) and by General Clinical Research Center grants from the National Center for Research Resources (NCRR).

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post- transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post- transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small- molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, Celgene, CV Therapeutics and Schering-Plough.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... considered nearly eradicated. Each year only a few hundred ... of Bonn, together with colleagues from Gabon, are reporting ... resist the vaccine protection to a considerable extent was ... in 2010. The pathogen could also potentially have infected ... the magazine PNAS . , The polio epidemic ...
(Date:8/21/2014)... Maryland (PRWEB) August 21, 2014 As ... the U.S. Pharmacopeial Convention (USP) has joined with the ... threat posed by the illegal online sale of medicines. ... benefits of medicines and foods is a core mission ... health around the world,” said Ronald T. Piervincenzi, chief ...
(Date:8/21/2014)... It's a terrible thing when a young adult, ... substance abuse issue. When that happens to a teenager in ... reliable help from the qualified substance abuse therapists at a ... easy for those young adults living in Pompano Beach, FL ... , Thankfully there is a new helpline operating for ...
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 David ... is a short but powerful collection of quotes from ... uplift and inspire other budding entrepreneurs on their challenging ... proud to announce the inclusion of President and Founder ... from highly successful and self-made celebrities such as Oprah ...
(Date:8/21/2014)... by T-type calcium channels in the thalamic reticular ... calcium. These channels enable thalamic reticular nucleus neurons ... enter a hyper-excited state. , In order to ... seizures, the researchers conducted an experiment to induce ... to delete the T-type calcium channel CaV3.3. The ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
... , FRIDAY, July 29 (HealthDay News) -- Some ethnic groups are ... organs as they gain weight, according to a new study. ... artery disease, is more common among people from South Asia, the ... journal PLoS ONE . "The new study showed South ...
... may also be contributing to hearing loss. Scientists mapped ... The distinctive roar of a Harley,s engine is ... noise for motorcyclists is actually generated by air whooshing ... sound can exceed safe levels. Now, scientists have identified ...
... testing at local emergency departments shows that hospitals miss opportunities ... with HIV, even when a regular testing program is in ... to the July issue of Annals of Emergency Medicine ... (CDC). The supplement includes a series of studies on HIV ...
... When people recognize voices, part of what helps make ... differently. But individuals with dyslexia don,t experience this familiar ... impairment." Tyler Perrachione with the Massachusetts Institute of ... language use the same words, they say those words ...
... protect skin cells from the sun,s ultraviolet radiation, according ... Barcelona and the CSIC (Spanish National Research Council). The ... in sun protection products. Ultraviolet (UV) rays emitted ... skin complaints, causing skin cancer, sunburn and solar erythema, ...
... The U.S. Food and Drug Administration should gather the ... the 35-year-old 510(k) clearance process for medical devices, says a ... process lacks the legal basis to be a reliable premarket ... devices and cannot be transformed into one, concluded the committee ...
Cached Medicine News:Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Dissecting dyslexia: Linking reading to voice recognition 2Health News:Dissecting dyslexia: Linking reading to voice recognition 3Health News:Grapes protect against ultraviolet radiation 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: